Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 20 04:00PM ET
55.00
Dollar change
-0.24
Percentage change
-0.43
%
Index- P/E20.41 EPS (ttm)2.69 Insider Own1.42% Shs Outstand191.76M Perf Week-3.98%
Market Cap10.55B Forward P/E13.16 EPS next Y4.18 Insider Trans-0.43% Shs Float189.06M Perf Month-8.23%
Income523.88M PEG0.61 EPS next Q0.84 Inst Own98.00% Short Float2.20% Perf Quarter-23.18%
Sales2.92B P/S3.61 EPS this Y57.82% Inst Trans0.95% Short Ratio2.04 Perf Half Y-16.08%
Book/sh30.21 P/B1.82 EPS next Y19.85% ROA7.47% Short Interest4.15M Perf Year-35.31%
Cash/sh6.63 P/C8.29 EPS next 5Y33.31% ROE9.64% 52W Range52.93 - 94.85 Perf YTD-16.32%
Dividend Est.- P/FCF16.90 EPS past 5Y- ROIC8.20% 52W High-42.01% Beta0.18
Dividend TTM- Quick Ratio3.49 Sales past 5Y10.98% Gross Margin78.25% 52W Low3.91% ATR (14)1.49
Dividend Ex-Date- Current Ratio5.52 EPS Y/Y TTM152.10% Oper. Margin21.44% RSI (14)35.12 Volatility1.18% 1.15%
Employees3040 Debt/Eq0.11 Sales Y/Y TTM17.99% Profit Margin17.93% Recom1.52 Target Price96.81
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q108.02% Payout0.00% Rel Volume2.31 Prev Close55.24
Sales Surprise0.88% EPS Surprise39.21% Sales Q/Q12.72% EarningsMay 01 AMC Avg Volume2.04M Price55.00
SMA20-3.23% SMA50-6.61% SMA200-16.63% Trades Volume4,710,518 Change-0.43%
Date Action Analyst Rating Change Price Target Change
Feb-24-25Upgrade Oppenheimer Perform → Outperform $98
Nov-15-24Initiated Wolfe Research Outperform $95
Oct-30-24Downgrade William Blair Outperform → Mkt Perform
Oct-10-24Resumed Raymond James Outperform $79
Aug-20-24Upgrade Bernstein Mkt Perform → Outperform $94 → $110
May-17-24Downgrade Robert W. Baird Outperform → Neutral $104 → $72
May-14-24Initiated Evercore ISI Outperform $113
Nov-15-23Initiated Wells Fargo Overweight $100
Oct-23-23Upgrade Bernstein Underperform → Mkt Perform $82
Sep-28-23Initiated Raymond James Mkt Perform
Jun-20-25 05:00PM
Jun-15-25 05:26AM
Jun-11-25 09:40AM
Jun-09-25 09:45AM
Jun-05-25 03:06AM
11:40AM Loading…
May-28-25 11:40AM
May-26-25 09:40AM
May-22-25 12:35PM
09:45AM
May-20-25 10:55AM
May-19-25 09:06AM
04:22AM
May-18-25 08:17AM
May-17-25 01:30PM
May-16-25 09:37AM
09:37AM Loading…
09:37AM
08:26AM
07:30AM
06:34AM
May-14-25 07:48AM
May-12-25 09:05AM
May-09-25 09:40AM
04:41AM
12:37AM
May-07-25 04:11PM
May-06-25 09:45AM
May-05-25 09:50AM
May-02-25 05:57PM
01:23PM
08:13AM
03:16AM Loading…
03:16AM
May-01-25 07:30PM
07:25PM
05:15PM
04:17PM
04:05PM
Apr-29-25 11:38AM
Apr-27-25 01:13PM
Apr-23-25 08:47PM
09:40AM
08:44AM
Apr-21-25 10:16AM
Apr-18-25 09:45AM
Apr-17-25 10:00AM
09:00AM
Apr-16-25 10:00AM
09:53AM
Apr-11-25 03:06AM
Apr-10-25 12:10PM
08:17AM
02:37AM
Apr-09-25 03:00PM
Apr-08-25 09:56AM
Apr-07-25 01:22PM
12:45PM
12:00PM
11:40AM
09:40AM
Apr-03-25 03:37PM
10:14AM
04:54AM
Apr-02-25 03:06PM
09:48AM
09:45AM
09:00AM
Mar-28-25 09:50AM
Mar-27-25 10:10AM
05:06AM
Mar-26-25 05:11AM
Mar-25-25 09:18PM
Mar-21-25 11:30AM
10:10AM
05:05AM
Mar-20-25 03:25PM
09:00AM
Mar-19-25 05:05AM
Mar-18-25 05:55AM
Mar-17-25 09:45AM
Mar-12-25 12:45PM
09:55AM
09:50AM
Mar-11-25 09:01AM
05:03AM
Mar-05-25 09:40AM
Mar-04-25 04:03AM
Feb-28-25 09:45AM
Feb-25-25 09:00AM
08:03AM
08:03AM
Feb-24-25 04:05PM
12:45PM
10:24AM
09:55AM
09:37AM
Feb-21-25 09:25AM
06:00AM
Feb-20-25 05:56PM
02:42PM
01:50PM
09:39AM
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burkhart ErinGVP, Chief Accounting OfficerMay 20 '25Sale59.311,786105,92814,173May 20 05:58 PM
Burkhart ErinOfficerMay 20 '25Proposed Sale59.311,786105,928May 20 09:58 AM
Hubbard CristinEVP, Chief Commercial OfficerMay 02 '25Sale64.9227317,72332,700May 06 05:07 PM
Hubbard CristinOfficerMay 02 '25Proposed Sale64.9227317,723May 02 10:05 AM
Burkhart ErinGVP, Chief Accounting OfficerMar 19 '25Sale71.521,29592,61816,955Mar 20 07:38 PM
Burkhart ErinOfficerMar 19 '25Proposed Sale71.521,29592,618Mar 19 09:36 AM
Guyer Charles GregEVP, Chief Technical OfficerMar 06 '25Sale71.287,034501,35587,655Mar 07 04:06 PM
Guyer Charles GregOfficerMar 06 '25Proposed Sale71.287,034501,359Mar 06 04:05 PM
Burkhart ErinGVP, Chief Accounting OfficerFeb 24 '25Sale68.381,34491,90313,105Feb 25 08:21 PM
Burkhart ErinOfficerFeb 24 '25Proposed Sale68.381,34491,903Feb 24 10:26 AM
Guyer Charles GregEVP, Chief Technical OfficerNov 12 '24Sale66.375,278350,32468,909Nov 14 02:44 PM
Guyer Charles GregOfficerNov 12 '24Proposed Sale66.375,278350,324Nov 12 02:27 PM
Burkhart ErinGVP, Chief Accounting OfficerAug 13 '24Sale90.0071464,26014,449Aug 15 03:57 PM
Burkhart ErinOfficerAug 13 '24Proposed Sale90.0071464,260Aug 13 11:48 AM